Kazia Therapeutics (KZIA) Accounts Payables (2009 - 2025)

Kazia Therapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $6.3 million for Q4 2025.

• Quarterly Accounts Payables fell 7.39% year-over-year to $6.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.3 million (down 7.39% YoY) and the FY2025 annual result came in at $6.5 million, down 34.75% from the prior year.
• Accounts Payables was $6.3 million for Q4 2025 at Kazia Therapeutics, down from $6.5 million in the prior quarter.
• Across five years, Accounts Payables topped out at $9.9 million in Q2 2024 and bottomed at $2.1 million in Q4 2022.
• A 5-year average of $5.0 million and a median of $4.3 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables sank 56.58% — and 2024, when it jumped 243.19%.
• Kazia Therapeutics' Accounts Payables stood at $4.8 million in 2021, then plunged by 56.58% to $2.1 million in 2022, then soared by 88.38% to $3.9 million in 2023, then surged by 75.51% to $6.8 million in 2024, then dropped by 7.39% to $6.3 million in 2025.
• Business Quant data shows KZIA's Accounts Payables at $6.3 million in Q4 2025, $6.5 million in Q2 2025, and $6.8 million in Q4 2024.